Followers | 221 |
Posts | 13482 |
Boards Moderated | 10 |
Alias Born | 06/20/2022 |

Thursday, January 30, 2025 1:14:26 PM

//////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
PS: Just a REVERSE SPLIT routine??? Hope ya scored MONSTER somehow on those Warrants, though!!!
Recent OCEA News
- Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development • GlobeNewswire Inc. • 02/10/2025 01:00:00 PM
- Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway • GlobeNewswire Inc. • 01/29/2025 01:30:00 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/22/2024 09:45:00 PM
- Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter • GlobeNewswire Inc. • 10/22/2024 08:45:00 PM
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses • GlobeNewswire Inc. • 10/01/2024 12:01:00 PM
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms • GlobeNewswire Inc. • 08/27/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:30:33 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 08/23/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 09:26:10 PM
- Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 • GlobeNewswire Inc. • 06/05/2024 11:01:00 AM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 05/30/2024 11:44:00 AM
- Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease • GlobeNewswire Inc. • 05/16/2024 12:01:00 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K • GlobeNewswire Inc. • 04/24/2024 08:51:06 PM
- Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL • GlobeNewswire Inc. • 03/28/2024 12:01:00 PM
UAV Corp. to Present Critical Inflation Test in 30 Days, Paving the Way to Secure Over $525 Million in DART Series Sales Contracts • UMAV • Mar 14, 2025 1:00 PM
Fifty 1 Labs, Inc. Completes Name and Symbol Change, Advances Toward Regaining 15c211 Compliance • FITY • Mar 14, 2025 10:30 AM
WIN-LIGHT GLOBAL FILES SEC SCHEDULE 13G DISCLOSING 1.96M SHARES OF PASSIVE INSTITUTIONAL INVESTOR OWNERSHIP • CNTM • Mar 14, 2025 7:13 AM
The Crypto Company Expands Leadership Team With Experienced Financial and Blockchain Professionals • CRCW • Mar 13, 2025 9:23 AM
ConnectM Announces $10 Million Share Repurchase Program • CNTM • Mar 13, 2025 9:13 AM
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making • SIGY • Mar 12, 2025 9:41 AM